ZA9710182B - Use of GLP-1 peptides. - Google Patents

Use of GLP-1 peptides.

Info

Publication number
ZA9710182B
ZA9710182B ZA9710182A ZA9710182A ZA9710182B ZA 9710182 B ZA9710182 B ZA 9710182B ZA 9710182 A ZA9710182 A ZA 9710182A ZA 9710182 A ZA9710182 A ZA 9710182A ZA 9710182 B ZA9710182 B ZA 9710182B
Authority
ZA
South Africa
Prior art keywords
glp
peptides
satiety
appetite
analogue
Prior art date
Application number
ZA9710182A
Other languages
English (en)
Inventor
Liselotte Bjerre Knudsen
Lars Thim
Martin Edward Judge
Jens Juul Holst
Arne Vernon Astrup
Birgitte Schjellerup Wulff
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8102971&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA9710182(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of ZA9710182B publication Critical patent/ZA9710182B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA9710182A 1996-11-12 1997-11-12 Use of GLP-1 peptides. ZA9710182B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK127096 1996-11-12

Publications (1)

Publication Number Publication Date
ZA9710182B true ZA9710182B (en) 1998-05-12

Family

ID=8102971

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9710182A ZA9710182B (en) 1996-11-12 1997-11-12 Use of GLP-1 peptides.

Country Status (9)

Country Link
US (5) US20030232754A1 (de)
EP (2) EP0941114B1 (de)
JP (1) JP2001504105A (de)
AT (2) ATE366584T1 (de)
AU (1) AU4863797A (de)
DE (2) DE69737916T2 (de)
ES (2) ES2290799T3 (de)
WO (1) WO1998020895A1 (de)
ZA (1) ZA9710182B (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US7223727B2 (en) 1998-04-09 2007-05-29 Serono Genetics Institute S.A. GSSP4 polynucleotides and polypeptides and uses thereof
US6720407B1 (en) * 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
US6927214B1 (en) 1999-01-15 2005-08-09 Novo Nordisk A/S Non-peptide GLP-1 agonists
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
WO2001000654A2 (en) 1999-06-29 2001-01-04 Pharmaceutical Discovery Corporation Purification and stabilization of peptide and proteins in pharmaceutical agents
WO2001032200A1 (en) * 1999-11-03 2001-05-10 Novo Nordisk A/S Use of a growth hormone or a growth hormone secretagogue for appetite-suppression or induction of satiety
KR20020093150A (ko) * 2000-05-16 2002-12-13 가부시키가이샤산와카가쿠켄큐쇼 인슐린 저항성 및/또는 비만 예방제 혹은 개선제
ES2312594T3 (es) * 2001-02-09 2009-03-01 Serono Genetics Institute S.A. Polinucleotidos y polipeptidos gssp4 y usos de los mismos.
WO2003026591A2 (en) 2001-09-24 2003-04-03 Imperial College Innovations Ltd. Modification of feeding behavior
EP2261250B1 (de) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin Fusionsproteine
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
NZ534125A (en) 2002-02-20 2006-11-30 Emisphere Tech Inc A formulation comprising a GLP-1 compound and a delivery agent
EP1894591B1 (de) 2002-03-20 2013-06-26 MannKind Corporation Kartusche für eine Inhalationsvorrichtung
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP2298337B1 (de) 2003-12-09 2017-02-22 Novo Nordisk A/S Regulierung des bevorzuchtes nahrungsaufnahmen mit verwendung von GLP-1 agonisten
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
EP1729795B1 (de) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albuminfusionsproteine
EP2100904B1 (de) 2004-04-23 2010-07-07 ConjuChem Biotechnologies Inc. Festphase zur Verwendung in einem Verfahren zur Reinigung von Albuminkonjugaten
JP2008501765A (ja) 2004-06-11 2008-01-24 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
CN104436170B (zh) 2004-08-23 2018-02-23 曼金德公司 用于药物输送的二酮哌嗪盐
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
MX2008001468A (es) 2005-06-30 2008-04-07 Sod Conseils Rech Applic Composiciones farmaceuticas del peptido similar al glucagon-1.
HUE028623T2 (en) 2005-09-14 2016-12-28 Mannkind Corp Active substance formulation method based on increasing the affinity of the active ingredient for binding to the surface of crystalline microparticles
ES2397289T3 (es) 2005-09-22 2013-03-06 Biocompatibles Uk Ltd. Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
US8293869B2 (en) 2005-12-16 2012-10-23 Nektar Therapeutics Polymer conjugates of GLP-1
IN2015DN00888A (de) 2006-02-22 2015-07-10 Mannkind Corp
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
DE602006009631D1 (de) 2006-05-10 2009-11-19 Biocompatibles Uk Ltd GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
KR101193722B1 (ko) * 2006-07-24 2013-01-11 바이오렉시스 파마슈티칼 코포레이션 엑센딘 융합 단백질
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
CN101868476B (zh) 2007-09-05 2015-02-25 诺沃-诺迪斯克有限公司 胰高血糖素样肽-1衍生物及其制药用途
WO2009055740A2 (en) * 2007-10-24 2009-04-30 Mannkind Corporation Method of preventing adverse effects by glp-1
BRPI0818874A2 (pt) * 2007-10-24 2015-05-05 Mannkind Corp Liberação de agentes ativos
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
ES2570400T3 (es) 2008-06-13 2016-05-18 Mannkind Corp Un inhalador de polvo seco y un sistema para el suministro de fármacos
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
JP5479465B2 (ja) 2008-06-20 2014-04-23 マンカインド コーポレイション 吸入努力をリアルタイムにプロファイルする対話式機器および方法
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2216042A1 (de) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP1-analoge pharmazeutische Zusammensetzungen
EP2405963B1 (de) 2009-03-11 2013-11-06 MannKind Corporation Gerät, system und verfahren zur messung von widerstand in einem inhaliergerät
KR101875969B1 (ko) 2009-06-12 2018-07-06 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
KR102668834B1 (ko) 2009-11-27 2024-05-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
MX359281B (es) 2010-06-21 2018-09-21 Mannkind Corp Sistema y metodos para suministrar un farmaco en polvo seco.
RU2013103763A (ru) 2010-07-02 2014-08-10 Ангиохем Инк. Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
MX345501B (es) 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
MX353285B (es) 2011-04-01 2018-01-05 Mannkind Corp Paquete de blister para cartuchos farmaceuticos.
MX355361B (es) 2011-04-12 2018-04-17 Novo Nordisk As Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CN103945859A (zh) 2011-10-24 2014-07-23 曼金德公司 用于治疗疼痛的方法和组合物
US20130172244A1 (en) * 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
MY171146A (en) 2012-03-22 2019-09-27 Novo Nordisk As Compositions of glp-1 peptides and preparation thereof
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP2863895B1 (de) 2012-06-20 2021-04-14 Novo Nordisk A/S Tablettenformulierung enthaltend ein peptid und einen adsorptionsvermittler
WO2014012069A2 (en) 2012-07-12 2014-01-16 Mannkind Corporation Dry powder drug delivery systems and methods
EP2911690A1 (de) 2012-10-26 2015-09-02 MannKind Corporation Inhalierbare influenza-impfstoffzusammensetzungen und verfahren
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
PE20151770A1 (es) 2013-05-28 2015-12-11 Takeda Pharmaceutical Compuesto peptidico
KR102321339B1 (ko) 2013-07-18 2021-11-02 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
WO2017204219A1 (ja) 2016-05-24 2017-11-30 武田薬品工業株式会社 ペプチド化合物
EP4233840A3 (de) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Kombinationen aus linagliptin und metformin
KR102647171B1 (ko) 2018-02-02 2024-03-15 노보 노르디스크 에이/에스 Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물
CN113181346A (zh) * 2018-03-09 2021-07-30 上海仁会生物制药股份有限公司 用于治疗肥胖和体重管理的glp-1组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) * 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5418218A (en) * 1992-07-10 1995-05-23 The University Of Maryland At Baltimore Histidyl-proline diketopiperazine (cyclo his-pro) a cns-active pharmacologic agent
US5380872A (en) * 1992-07-14 1995-01-10 Glaxo Inc. Modulators of cholecystokinin
DK1975177T3 (da) * 1996-03-01 2011-07-25 Novo Nordisk As Appetitundertrykkende peptid, formuleringer dermed og anvendelse deraf
US5912229A (en) * 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) * 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
JP4798814B2 (ja) * 1997-01-07 2011-10-19 アミリン・ファーマシューティカルズ，インコーポレイテッド 食物摂取低減用のエキセンジンおよびそのアゴニストの使用
PT1003581E (pt) * 1998-01-30 2001-04-30 Novo Nordisk As Seringa de injeccao
US6420137B1 (en) * 1998-11-25 2002-07-16 American Home Products Corporation Nucleic acid encoding human neurotensin subtype 2 receptor
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6399089B1 (en) * 2000-05-15 2002-06-04 A. Glenn Braswell Compositions and methods for regulating metabolism and balancing body weight
US20020187926A1 (en) * 2001-03-07 2002-12-12 Knudsen Liselotte Bjerre Combined use of derivatives of GLP-1 analogs and PPAR ligands
US7041646B2 (en) * 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists

Also Published As

Publication number Publication date
AU4863797A (en) 1998-06-03
ES2290799T3 (es) 2008-02-16
EP1529534A2 (de) 2005-05-11
US20090149387A1 (en) 2009-06-11
DE69737916D1 (de) 2007-08-23
US20100113363A1 (en) 2010-05-06
US20030232754A1 (en) 2003-12-18
EP1529534A3 (de) 2005-06-08
US20110028391A1 (en) 2011-02-03
ATE366584T1 (de) 2007-08-15
ATE289517T1 (de) 2005-03-15
JP2001504105A (ja) 2001-03-27
EP0941114B1 (de) 2005-02-23
DE69737916T2 (de) 2008-04-03
DE69732572D1 (de) 2005-03-31
EP1529534B1 (de) 2007-07-11
US20070161568A1 (en) 2007-07-12
EP0941114A1 (de) 1999-09-15
ES2237790T3 (es) 2005-08-01
DE69732572T2 (de) 2005-12-29
WO1998020895A1 (en) 1998-05-22

Similar Documents

Publication Publication Date Title
ZA9710182B (en) Use of GLP-1 peptides.
AU8402691A (en) Dental curing lamp and apparatus
GB2282811B (en) Vaccine for the prevention of porcine reproductive and respiratory syndrome
EP0605442A4 (de) Rekombinante antikörper zur humanen therapie.
HUP9901186A3 (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
AU4564696A (en) Recombinant agents affecting haemophilia
EP0906310A4 (de) Oxadiazol-benzosulfonamide als selektive beta-3 adrenergische rezeptor agonisten zur behandlung von diabetis und fettleibigkeit
GB2318055A (en) Dosage form comprising oxybutynin
GB9907461D0 (en) Neurite regeneration
BG100974A (en) Vaccines against papillomavirus
PL294269A1 (en) Two-part fistula apparatus and uniting ring therefor
AU7960598A (en) Recombinant porcine reproductive and respiratory syndrome virus (prrsv) for use as a vaccine
AU6027190A (en) Elevating table for pelvis correction
AU6856094A (en) Oxadiazole derivative and medicinal composition thereof
AU9088891A (en) Diagnostic and therapeutic compositions and methods for lipoprotein(a)
AU7617791A (en) Recombinant immunocastration vaccine
MY129782A (en) Novel medical use
GB2317109B (en) A therapeutic composition for the treatment and repair of connective tissue in mammals
AU2004595A (en) Process for preparing recombinant aprotinin and recombinant aprotinin variants having the natural N-terminal sequence
HUP9903340A3 (en) Novel devices for transdermal administering of trimegestone and producing these
AU2623088A (en) New anti-receptor peptides and therapeutic agents
AU3152089A (en) Method and composition for ophthalmic anesthesia using rodocaine
AU1649592A (en) Recombinant immunocastration vaccine and polypeptides useful for same
AU4727793A (en) Time registering and scoring apparatus for billiards table games
NZ333652A (en) Inhibition of human rotavirus infection using kappa-casein